+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Myelodysplastic Syndrome (MDS) Treatment Market - Growth, Trends, and Forecast (2020-2025)

  • ID: 4997394
  • Report
  • March 2020
  • Region: Global
  • 114 pages
  • Mordor Intelligence
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie
  • Accord Healthcare
  • Bristol-Myers Squibb
  • Jazz Pharmaceuticals, Inc
  • Lupin
  • Novartis
  • MORE
The global myelodysplastic syndrome (MDS) treatment market is expected to grow significantly over the forecast period owing to the increasing pipeline products and product approvals and R&D investments in the development of novel drugs for Myelodysplastic Syndrome (MDS). In 2018, Lupin had received approval for its Decitabine for Injection, 50 mg/vial, Single-Dose Vial from the United States Food and Drug Administration (FDA) to market a generic version of Otsuka Pharmaceutical Co. Ltd.'s Dacogen for Injection, 50 mg/vial, Single-Dose Vial. However, side effects associated with the chemotherapy medications might hamper the growth of the market studied.

Key Market Trends

Stem Cell Transplant segment Holds a Significant Share in the Market Studied
  • Stem Cell Transplantation (SCT) offers a potentially beneficial therapy for the patients with myelodysplastic syndromes.
  • There are two major types of SCT, one is allogeneic stem cell transplant and the other is an autologous stem cell transplant.
  • For an allogeneic stem cell transplant, after the bone marrow is destroyed, the patient receives blood-forming stem cells from another person, the donor. This is the type of transplant typically used for MDS.
  • In an autologous stem cell transplant, the patient gets back their own stem cells (which were removed before treatment). This type of transplant is not typically used for patients with MDS because the patient's bone marrow contains abnormal stem cells.
North America dominate the Global Myelodysplastic Syndrome Treatment Market
  • North America dominates the global MDS treatment market owing to the increase in prevalence of Myelodysplastic Syndrome, early adoption of the novel treatments, high R&D investments on the development of the novel drugs, presence of sophisticated healthcare infrastructure.
  • For instance, In December 2019, Bristol-Myers Squibb and Acceleron Pharma announced the FDA Advisory Committee will review Reblozyl (luspatercept-aamt) for use in patients with Myelodysplastic Syndrome.
  • Asia Pacific is expected to experience a lucrative growth in the Global Myelodysplastic Syndrome Treatment market due to the developing healthcare infrastructure, rapidly improving economic conditions, and promising regulatory environment for new Treatment.
Competitive Landscape

In the market studied, major players are focused on expanding their business in different areas by adopting various market strategies such as partnerships, collaborations, acquisitions and mergers etc. AbbVie, Accord Healthcare, Bristol-Myers Squibb, Celgene Corporation, Takeda Pharmaceutical Company Limited , Novartis AG are the major market players among others.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • Accord Healthcare
  • Bristol-Myers Squibb
  • Jazz Pharmaceuticals, Inc
  • Lupin
  • Novartis
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High R&D investments on Development of Novel Treatments for MDS
4.2.2 Strong Presence of Pipeline Drugs
4.3 Market Restraints
4.3.1 Side Effects Associated with the Medications
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Treatment Type
5.1.1 Chemotherapy
5.1.2 Immune Treatments
5.1.3 Stem Cell Transplant
5.1.4 Others
5.2 By End-User
5.2.1 Hospitals
5.2.2 Specialty Clinics
5.2.3 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie
6.1.2 Accord Healthcare
6.1.3 Bristol-Myers Squibb
6.1.4 Jazz Pharmaceuticals, Inc
6.1.5 Novartis
6.1.6 Lupin
6.1.7 Otsuka America Pharmaceutical, Inc.
6.1.8 Onconova Therapeutics
6.1.9 Takeda Pharmaceutical Company Limited

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie
  • Accord Healthcare
  • Bristol-Myers Squibb
  • Jazz Pharmaceuticals, Inc
  • Novartis
  • Lupin
  • Otsuka America Pharmaceutical, Inc.
  • Onconova Therapeutics
  • Takeda Pharmaceutical Company Limited
Note: Product cover images may vary from those shown
Adroll
adroll